14136
document
The adrenocorticotrophic hormone ( 4-9 ) analog ORG 2766 benefits autistic children : report on a second controlled clinical trial . In a second controlled crossover trial , 20 autistic children received 40 mg/day of the neuropeptide ORG 2766 , a synthetic analog of ACTH ( 4-9 ) , for 8 weeks . Parents ' checklist ratings ( ABC ) as well as clinicians ' ratings ( CGI ) pointed to significant improvements after the course of treatment ; improvements were clearest on the ABC social withdrawal subscale . The analysis of individual target symptoms and the parents ' treatment preferences substantiated the beneficial effects of ORG 2766 . In an ethologically analyzed playroom session , ORG 2766 treatment was associated with an improvement in the children 's play behavior and a significant increase in the social interaction between child and experimenter . Gaze coordination between child and experimenter also was improved .
14137
Intervention_Pharmacological
adrenocorticotrophic hormone ( 4-9 ) analog ORG 2766
14138
Intervention_Pharmacological
40 mg/day of the neuropeptide ORG 2766 , a synthetic analog of ACTH ( 4-9 )
14139
Intervention_Pharmacological
ORG 2766 .
14140
Outcome_Other
Parents ' checklist ratings ( ABC )
14141
Outcome_Other
clinicians ' ratings ( CGI )
14142
Outcome_Other
ABC social withdrawal subscale .
14143
Outcome_Mental
children 's play behavior
14144
Outcome_Mental
social interaction between child and experimenter . Gaze coordination